Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 10/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23375120 | 0.92 | SLC10A2 (0.44) | SLC10A2LMNANR1H4KMT2ATDP1 | |
| SCHEMBL23375162 | 0.92 | LMNA (0.39) | SLC10A2LMNANR1H4KMT2APSEN1 | |
| SCHEMBL23375163 | 0.90 | SLC10A2 (0.39) | SLC10A2NR1H4PSEN1PSEN2APH1B | |
| SCHEMBL23375156 | 0.88 | SLC10A2 (0.38) | SLC10A2NR1H4KMT2APSEN1PSEN2 | |
| SCHEMBL22286375 | 0.88 | SLC10A2 (0.43) | SLC10A2 | |
| SCHEMBL22286519 | 0.87 | SLC10A2 (0.44) | SLC10A2NR1H4KMT2A | |
| SCHEMBL22286418 | 0.86 | SLC10A2 (0.39) | SLC10A2NR1H4ALDH1A1 | |
| SCHEMBL23375103 | 0.85 | SLC10A2 (0.39) | SLC10A2NR1H4OPRM1OPRL1 | |
| SCHEMBL7679504 | 0.84 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL7672309 | 0.84 | SLC10A2 (0.44) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114786773-B | Benzothiazaheterocycles Heptatriene compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-10-18 | — | — | CN | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885LMNA 2925/4885NR1H4 6/4885 |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885LMNA 3098/4885NR1H4 6/4885 |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885LMNA 2925/4885NR1H4 6/4885 |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885LMNA 2925/4885NR1H4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.